Mirvetuximab soravtansine
Approved · EMAAlso known as Elahere.
Recent clinical, regulatory, research and industry developments relating to this drug.
Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Elahere as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian,… Show full indicationShow less
Elahere as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Gynecologic oncology1
- International journal of gynecological cancer : official journal of the International Gynecological Cancer Society1
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology1
- Coleman RL2
- Oaknin A2
- Armetta J1
- Biorn M1
- Bogani G1
- Caveney B1
- Colombo N1
- Cooper M1
- Bon Secours Hospital and Clinical Trials1
- Centre Leon Berard1
- Dana Farber Cancer Institute1
- Dana-Farber Cancer Institute1
- European Institute of Oncology IRCCS1
- Fondazione Policlinico Universitario A. Gemelli1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 5 of the same disease areas as Mirvetuximab soravtansine in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.